Tau PET in Imaging and Cognition: Healthy Adults From 55-90
NCT03372317
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The investigators aim to use the new PET radioligand, 18F-MK-6240, to detect tau pathology in cognitive healthy and mild cognitive impairment (MCI) elders. The investigators will then examine the interactions between differential tau burden and performance on cognitive tasks, functional magnetic resonance imaging (fMRI) neural activation patterns, and other cognitive and behavioral measures.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Mild Cognitive Impairment
- Aging
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 55 to 90 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Yaakov Stern
- Last updated on ClinicalTrials.gov
- February 11, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New York · 1
- Columbia University Medical Center · New York, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.